A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

June 6, 2018

Study Completion Date

August 29, 2018

Conditions
Hepatitis C Virus (HCV)
Interventions
DRUG

Glecaprevir/Pibrentasvir

Fixed-dose combination tablets taken orally once a day.

Trial Locations (25)

1010

Auckland Clinical Studies Ltd /ID# 157033, Auckland

2193

Wits Clinical Research Site /ID# 157038, Johannesburg

2747

Nepean Hospital Kingswood /ID# 157027, Kingswood

3000

UZ Leuven /ID# 157030, Leuven

3050

Royal Melbourne Hospital /ID# 157024, Parkville

4029

Royal Brisbane and Women's Hospital /ID# 157025, Herston

7925

University of Cape Town /ID# 157039, Cape Town

8500

AZ Groeninge /ID# 157029, Kortrijk

19141

Einstein Medical Center /ID# 157436, Philadelphia

33604

Hopital Haut-Lévêque /ID# 157035, Pessac

63100

CHU Estaing /ID# 157034, Clermont-Ferrand

75012

Hopital Saint Antoine /ID# 157036, Paris

90048

Cedars-Sinai Medical Center - West Hollywood /ID# 157045, West Hollywood

92105

Research & Education, Inc. /ID# 157042, San Diego

92110

Hopital Beaujon /ID# 157028, Clichy

92154

Kaiser Permanente /ID# 157044, San Diego

94110

Zuckerberg San Francisco Gener /ID# 157040, San Francisco

98109

University of Washington /ID# 157041, Seattle

100000

National Hospital of Tropical Diseases /ID# 162282, Hanoi

119074

National University Hospital /ID# 156855, Singapore

169608

Singapore General Hospital /ID# 157037, Singapore

700000

Hoa Hao Medic Co. Ltd. /ID# 162283, Ho Chi Minh City

T2N 4Z6

University of Calgary /ID# 157031, Calgary

M5G 2C4

Toronto General Hospital /ID# 157032, Toronto

Unknown

Tropical Diseases Hospital /ID# 162281, Ho Chi Minh City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY